Hydroxychloroquine Drug’s Clinical Trials End Due to Safety Concerns
Health

Hydroxychloroquine Drug’s Clinical Trials End Due to Safety Concerns 

Last updated on May 29th, 2020

The World Health Organisation has announced to end the clinical trials of hydroxychloroquine drug against COVID 19 amid rising safety concerns. The decision came after Lancet medical journal’s recently published scientific study ruled out the benefits of hydroxychloroquine on COVID-19 patients after the drug led to an increased death rate and heart complications.

“The executive group (of a four arm drug trial undertaken by the WHO to find a weapon against the pandemic virus) has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board,” said WHO director general Tedros Adhanom Ghebreyesus in Geneva.

WHO started the Solidarity Trial, under which the safety and efficiency of four drugs and drug combinations is being evaluated against COVID-19 from two months. As per WHO, close to 3,500 patients have been enrolled from 17 nations under the trial.

The drug caught people’s attention after the US President, Donald Trump’s tweets about miraculous effect of the drug taken together with AZITHROMYCIN took the internet by storm. Trump also mentioned that he is taking the drugs as a preventive measure. The drug has been used on patients in numerous countries including the US, India, Mauritius, Seychelles, Russia, and the United Arab Emirates.

Earlier this month, a group of Chinese researchers came to the same conclusion. In a study published in British Medical Journal, it was concluded that administration of hydroxychloroquine did not come up with any significant result, instead it adversely increased the death rate and irregular heart rate among the patients.

WHO has been warning about the adverse effects of the hydroxychloroquine drug since it came in discussion that the FDI was looking forward to the drug as possible treatment of battling COVID-19.

Meanwhile in India, the health authorities have been recommended to continue using the drug with ‘strict and limited’ usage over patients. “We found there were no major side effects except for nausea, vomiting, palpitation occasionally. Hence in our advisory we have recommended that HCQ should be continued for prophylaxis as there is no harm. Benefit may be there,” ICMR chief Balram Bhargava said. Multiple nations are already in a race to finish first as the creator of a workable vaccine. Clinical trials at global level are taking place to strengthen the fight against the pandemic. Many nations have decided to ease down lockdown restrictions despite the virus fear in order to avoid freefall of the economies that has brought multiple countries at the brink of recession and shrinking GDPs. But the hunt for vaccine must go on in order to find a rock-solid solution in the fight against the coronavirus.

Related posts